Compass Therapeutics (CMPX) Liabilities and Shareholders Equity (2018 - 2026)

Compass Therapeutics has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $205.2 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 56.08% year-over-year to $205.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $772.7 million (up 34.01% YoY) and the FY2025 annual result came in at $219.6 million, up 56.4% from the prior year.
• Liabilities and Shareholders Equity fell to $205.2 million in Q1 2026 per CMPX's latest filing, from $219.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $231.3 million in Q3 2025 and troughed at $116.7 million in Q2 2025.
• A 5-year average of $165.8 million and a median of $156.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 266.31% in 2022, then decreased 25.01% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $199.6 million in 2022, then slipped by 21.42% to $156.9 million in 2023, then decreased by 10.5% to $140.4 million in 2024, then surged by 56.4% to $219.6 million in 2025, then fell by 6.57% to $205.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $205.2 million, $219.6 million, and $231.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.